Moogali Arvind

Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial

Tae Won Yi, Brendan Smyth, Gian Luca Di Tanna, Clare Arnott et autres

RATIONALE & OBJECTIVE: It is unclear whether the effect of canagliflozin on adverse kidney and cardiovascular events in those with diabetic kidney disease varies by age and sex. We assessed the effects of canagliflozin among age group categories and between sexes in …

ca, au, us, nl, gb, cn (code pays fourni par la source)

Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease

Zien Zhou, Meg Jardine, Qiang Li, Brendon L. Neuen et autres

Background and Purpose: Chronic kidney disease with reduced estimated glomerular filtration rate or elevated albuminuria increases risk for ischemic and hemorrhagic stroke. This study assessed the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on stroke and atrial fibrillation/flutter (AF/AFL) from CREDENCE …

cn, au, us, nl, ca, gb (code pays fourni par la source)

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Deepak L. Bhatt, Philippe Gabríel Steg, Shamir R Mehta, Lawrence A. Leiter et autres

us, fr, gb, ca, se, ar, jp, au (code pays fourni par la source)